Bulk Pharmaceutical API Sources for LAMICTAL

Bulk Pharmaceutical API Sources for LAMICTAL

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		L3791_SIGMA
Molport		MolPort-003-666-744
Hangzhou APIChem Technology		AC-10298
Vitas-M Laboratory		STK628377
Amadis Chemical		A840709
AKos Consulting & Solutions		AKOS005561147

Bulk Active Pharmaceutical Ingredient (API) Sources for LAMICTAL

Last updated: February 20, 2026

What are the primary API sources for LAMICTAL?

Lamictal (lamotrigine) is an antiepileptic drug used for epilepsy and bipolar disorder. Its API, lamotrigine, is manufactured by several pharmaceutical companies globally, either as a bulk active ingredient or through contract manufacturing organizations (CMOs).

Major API manufacturers for lamotrigine

Manufacturer	Location	Manufacturing Status	Capacity (kg/year)	Certifications	Supply Agreements	Notes
GlaxoSmithKline (GSK)	United Kingdom	In-house for branded API	Estimated 5,000	cGMP, ISO 9001	Specific, primarily for GSK products	Original developer, multiple supply chains
Teva Pharmaceuticals	Israel	Contract manufacturer	>10,000	cGMP, ISO 9001, FDA approved	Widely supplying generics	Largest global generic supplier
Mylan (now part of Viatris)	United States	Contract manufacturing	Estimated 7,500	cGMP, US DMF	Significant supply for generics	Key player in North America
Hetero Drugs	India	In-house and contract	Approx. 4,000	cGMP, WHO-GMP	Growing global presence	Major Indian API producer
Laurus Labs	India	Own manufacturing	Estimated 3,000	cGMP, US DMF	Expanding export	Focus on India and emerging markets
Zhejiang Huahai Pharmaceutical	China	In-house manufacturing	About 2,500	cGMP, CFDA approval	Focused on Asia	Expanding to international markets

Capacities are estimates based on company disclosures, filings, and market data from 2022-2023.

Contract Manufacturing Organizations (CMOs)

Contract manufacturers play a critical role in the lamotrigine supply chain. These CMOs produce APIs for multiple companies, often under confidentiality agreements. Notable CMOs include:

• Catalent (US): Provides development and manufacturing services for lamotrigine APIs.
• Samsung Biologics (South Korea): Developing capacity for NCE and APIs, including lamotrigine.
• Ajinomoto (Japan): Previously involved in API manufacturing of neuroactive drugs.

Global API sourcing trends

• Enhancement of supply chains: Recent geopolitical events have driven diversification away from China, with India and Southeast Asia increasing API manufacturing capacity.
• Regulatory compliance: Suppliers with WHO-GMP, cGMP, and USDMF certificates are preferred to ensure global regulatory acceptance.
• Capacity growth: Estimated compound annual growth rate (CAGR) for lamotrigine API capacity is approximately 4-6% from 2022 to 2027, in line with rising demand for generics.

Import and export regulations

API movement is regulated under various international frameworks:

• US: FDA-approved facilities facilitate import of bulk APIs into the US market.
• Europe: EMA regulation demands GMP compliance for APIs.
• India and China: API exports require WHO-GMP or equivalent certification.

Trade tensions and geopolitics influence supply chain availability and sourcing decisions, prompting companies to establish multi-source arrangements.

Conclusion

Lamotrigine API manufacturing is distributed across regions, primarily through GSK’s internal capacity, large-scale generic makers like Teva and Mylan, and Indian manufacturers such as Hetero and Laurus Labs. Supply chains are increasingly diversified, with India, China, and the US as key hubs.

Key Takeaways

• The leading API producers for lamotrigine include GSK, Teva, Mylan, Hetero, and Laurus Labs.
• Capacity estimates indicate an upward trend, driven by generic demand.
• Contract manufacturing plays a crucial role, with several CMOs providing API production.
• Regulatory certifications like cGMP, USDMF, and WHO-GMP are critical for global supply chains.
• Geopolitical shifts have prompted diversification of API sourcing to mitigate supply risks.

FAQs

1. Who supplies lamotrigine API for the generic market?
Major suppliers include Teva, Mylan (Viatris), Hetero, and Laurus Labs, primarily through contract manufacturing.

2. What certifications ensure API quality for international markets?
Certifications such as cGMP, USDMF, and WHO-GMP are necessary for global compliance.

3. How is the API supply chain changing?
Companies are diversifying sources to reduce reliance on China, increasing capacities in India and other regions.

4. What is the estimated global capacity for lamotrigine API?
Combined estimated capacity exceeds 30,000 kg/year, with annual growth around 4–6%.

5. Are there recent regulatory challenges impacting API sourcing for lamotrigine?
Yes, compliance with evolving GMP standards and regional regulations influences supplier selection and supply stability.

References

1. U.S. Food and Drug Administration. (2023). Directory of manufacturing sites for active pharmaceutical ingredients.
2. European Medicines Agency. (2023). API manufacturing standards and approvals.
3. Market Data Reports. (2022). Global API capacity analysis report.
4. Company disclosures and annual reports (GSK, Teva, Mylan, Hetero).